The latest news, announcements and press releases from Contera Pharma.
Together, the companies will explore novel RNA-targeting treatment approaches designed to deliver transformative benefits for patients worldwide. The partnership will leverage Lundbeck’s more than 70 years of neuroscience experience and Contera Pharma’s oligonucleotide expertise and pioneering proprietary RNA discovery platforms, including AttackPoint discovery®, OligoDisc®, and SpliceMatrix®.
This is the News section of the company profile page for Contera Pharma on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.